BioPorto A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carsten Buhl
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Tuborg Havnevej 15 Hellerup CR Denmark 2900
- IPO Date
- Dec 13, 2019
- Website
- bioporto.com
- Similar Companies
- Business
- BioPorto A/S (Ticker: THOXF) is a Denmark-based diagnostics company that develops and markets in vitro diagnostic (IVD) tests focused on kidney injury biomarkers, primarily targeting acute kidney injury (AKI) and related conditions in clinical and research settings. The company offers specialized products such as the NGAL Test for early detection of AKI in patients undergoing cardiac surgery, critical care, and sepsis; the ProGRP Test for small cell lung cancer diagnosis; and the beta defensin-2 assay under development for inflammatory bowel disease; along with research-use-only kits and companion diagnostics services. These offerings serve healthcare providers, laboratories, and pharmaceutical companies worldwide, with a focus on point-of-care and centralized testing solutions. Founded in 2000 and headquartered in Hellerup, Denmark, BioPorto operates primarily in Europe and North America, with expanding presence in Asia through distribution partnerships. In recent developments, BioPorto secured a significant strategic collaboration with bioMérieux in 2024 to commercialize NGAL tests on automated immunoassay platforms, enhancing global accessibility; completed a DKK 100 million equity financing round in late 2024 to support R&D and market expansion; and launched regulatory submissions for expanded NGAL indications in the U.S. and EU during 2025, marking key milestones in its growth strategy.
Grant of Warrants
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
BioPorto announces Interim Result for the First Quarter of 2026
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
Notice convening the Annual General Meeting in BioPorto A/S
BioPorto announces the Annual Report for 2025
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update
BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.
BioPorto A/S to host an investor webcast on the results for the first half of 2025
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
BioPorto A/S to host first quarter 2025 earnings webcast for investors